iiinova — where your digital self keeps evolving

Reposted by Kevan Polkinghorne 🇳🇿

😱 Spooky SpectreKILLoquy 🔪 🩸 @caulimovirus.bsky.social · 08/03/2026

locums nephrology job in north island, new zealand gmedical.com/job/job-3166...

gmedical.com

Global Medical Staffing

1123

Reposted by Kevan Polkinghorne 🇳🇿

Iain Bressendorff, MD PhD @ibressendorff.bsky.social · 20/02/2026

@dialysisbloke.bsky.social Applied the VIPAR protocol to a patient with cAMR, first time in our centre. Fingers crossed for positive results 🤞🏻 Just wanted to let you know that it’s being used out there 🤓

131

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 20/02/2026

Nice. I will let Bill Mulley know. Hopefully goes well for your patient

010

Reposted by Kevan Polkinghorne 🇳🇿

CARI guidelines @cariguidelines.bsky.social · 15/12/2025

✅ New Clinical Guidance for Kidney Stone Management Managing kidney stones effectively requires timely decisions and tailored evaluation. This visual summary highlights key steps from acute presentation to post-stone evaluation:

033

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 13/12/2025

I could return to where I had my first job out of medical school….there was no nephrologist there then. I worked for the Gen Physican who looked after the dialysis patients as my first rotation after med school. Must have made an impression

010

Reposted by Kevan Polkinghorne 🇳🇿

Adnan Sharif @adnan-sharif.bsky.social · 08/12/2025

Delighted to see my Commentary published in the latest issue of #Circulation Journal Why We Must Rethink Kidney Transplantation as a Cardiovascular Risk–Reducing Intervention in Kidney Failure Disagree? Happy to be challenged 💪🏼 #StopCardiacTests Link to issue: www.ahajournals.org/toc/circ/cur...

ahajournals.org

Vol 152, No 23 | Circulation

046

Reposted by Kevan Polkinghorne 🇳🇿

Myra McGuinness @myramcguinness.bsky.social · 04/12/2025

Registration now open url.au.m.mimecastprotect.com/s/ZR0QCNLwzj... * Causal Inference with Hidden Confounding * Implementing the Estimand Framework in Clinical Trials * Pairwise and Network Meta-analysis: Fundamentals and Beyond * Cluster Randomised Trials: From Fundamentals to State-of-the-Art

url.au.m.mimecastprotect.com

ViCBiostat Summer School 2026

Welcome to the registration page for the 2026 Summer School courses. Full course descriptions can be found on our website:...

061

Reposted by Kevan Polkinghorne 🇳🇿

Joel Topf @kidneyboy.bsky.social · 03/12/2025

Stop complaining about pill burden in ESRD! There is no pill you are giving your dialysis patient that has data half as impressive as this study. If they are taking too many pills have them stop any of the dozen pills they are taking with ZEERO data in ESRD. #NephJC

3273

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 03/12/2025

Correct. Recruitment was super easy. Patients really liked the idea of a natural product.

020

Reposted by Kevan Polkinghorne 🇳🇿

Nephrology Journal Club @nephjc.bsky.social · 01/12/2025

Maybe the most shocking study from #KidneyWk. 🐚From the depths of the oceans to #BlueSky, we're discussing PISCES 🐟 12/2/25 9pm EST. #NephJC Are you hooked🪝on fish oil for CV disease in ESRD, or are you throwing it back 🌊? www.nephjc.com/news/pisces-fishoil

nephjc.com

Fish Oil in Dialysis: A Big Catch or an Empty Net — NephJC

Holy Mackerel! This week we will discuss fish oil use in maintenance hemodialysis patients. Could this be the one thing that bends the curve on CV mortality, or is it just a red herring?

02016

Reposted by Kevan Polkinghorne 🇳🇿

ANZVASC @anzvasc.bsky.social · 28/11/2025

The International Vasculitis Workshop is pleased to announce the full speaker lineup for the 2026 event in Melbourne! Explore the complete list and learn more about each speaker on the Workshop Website: vasculitis-melbourne2026.com/plenary-spea...

011

Reposted by Kevan Polkinghorne 🇳🇿

Dr Shane Huntington OAM @drshanerrr.bsky.social · 26/11/2025

The success rate for NHMRC Ideas Grants announced yesterday was just over 8%. That means 11 of every 12 people who applied got rejected. This is a culture changing level of rejection and frankly a point of national shame. This is a crisis for research. I will not rest until we see this resolved.

38832

Reposted by Kevan Polkinghorne 🇳🇿

ANZVASC @anzvasc.bsky.social · 26/11/2025

The program for the 22nd International Vasculitis Workshop has now launched! Filled with amazing plenary speakers and sessions. Visit the website vasculitis-melbourne2026.com/program-full/ and start planning your Workshop!

011

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 23/11/2025

Spent many a holiday there as a young adult. Check out Hahei of possible. A beautiful spot

030

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 23/11/2025

A Fantastic band from my home country. All their albums are excellent.

010

Reposted by Kevan Polkinghorne 🇳🇿

Nephrology Journal Club @nephjc.bsky.social · 19/11/2025

Up next: It might seem a little fishy, but was a great catch 🎣 #NephJC PISCES, the use of fish oil to decrease mortality in dialysis patients. www.pubmed.ncbi.nlm....

363

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 20/11/2025

I have no idea what time this is in Australia. I’ll have to try !

100

Reposted by Kevan Polkinghorne 🇳🇿

ViCBiostat @vicbiostat.bsky.social · 12/11/2025

Mark your diaries! The ViCBiostat Summer School returns from 13-20 Feb 2026, in Melbourne and online. Courses include causal inference, cluster randomised trials, meta-analysis and the estimand framework. Further details TBA shortly - sign up to our mailing list at www.vicbiostat.org.au #statistics

01510

Reposted by Kevan Polkinghorne 🇳🇿

JAMA @jama.com · 11/11/2025

Among more than 800 000 CKD-PC participants, discordance between cystatin C and creatinine eGFR values was associated with increased risk of death, cardiovascular events, and kidney failure. ja.ma/47A5Gdd

JAMA graph: Discordance in Creatinine- and Cystatin C-Based eGFR. Figure 2 shows association of estimated glomerular filtration rate difference with risks of long-term adverse outcomes. Hazard ratio vs. Difference between eGFRcys and eGFRcr, % for Death, CVD death, Heart failure, ASCVD, KFRT.

043

Reposted by Kevan Polkinghorne 🇳🇿

ANZVASC @anzvasc.bsky.social · 11/11/2025

Final Chance! Early bird registrations for the International Vasculitis Workshop 2026 close 14 November - and they won’t be extended again. Register at vasculitis-melbourne2026.com/registration/

001

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 10/11/2025

As the Australian PI I have to say I agree. PISCES took 10 years to do as best we could on minimal funding. The result is what it is - we will try to look further in to the data but given the low cost/ low risk what would be the point in doing another larger study? It would be hard to find funding

140

Reposted by Kevan Polkinghorne 🇳🇿

JAMA @jama.com · 07/11/2025

JAMA graph shows association of eGFR difference with risks of long-term adverse outcomes. Hazard ratio vs. difference between eGFRcys & eGFRcr (%). Lines for death, CVD death, heart failure, ASCVD, KFRT are plotted. Declining risk as difference approaches zero.

067

Reposted by Kevan Polkinghorne 🇳🇿

Cristina Popa @nephroseeker.medsky.social · 07/11/2025

In PISCES, daily n–3 fatty acids cut serious cardiovascular events in dialysis patients by nearly half (HR 0.57). Fish oil clearly had bigger fish to fry than placebo: fewer MIs, strokes, cardiac deaths without extra adverse catches @nejm.org #kidneywk sim publication www.nejm.org/doi/full/10....

nejm.org

Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis | NEJM

Cardiovascular disease is the leading cause of death in patients receiving hemodialysis, yet effective preventive therapies remain limited. Supplementation with n−3 polyunsaturated fatty acids, esp...

0123

Reposted by Kevan Polkinghorne 🇳🇿

Nayan Arora @captainchloride.bsky.social · 07/11/2025

Shocking first high impact trial of the day. Fish oil reduces CV events in dialysis patients! #Pisces #kidneywk Simultaneous pub in NEJM www.nejm.org/doi/full/10....

45616

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 07/11/2025

Very proud to have lead the Australian arm of PISCES. Huge thanks for Charmaine Lok for the collaboration.

052

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 07/11/2025

Recall only a few years ago that the late breaking trials session often has post hoc observation analyses or another negative HD or AKI trial. Indeed it is fantastic. More tomorrow…

011

Reposted by Kevan Polkinghorne 🇳🇿

ANZVASC @anzvasc.bsky.social · 07/11/2025

Make the most of Melbourne while visiting for the 22nd International Vasculitis Workshop! Explore hidden laneway cafes, explore the coast or unwind in the Royal Botanic Gardens. Check out the LOC Melbourne Guides: vasculitis-melbourne2026.com/loc-melbourn...

011

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 06/11/2025

Yes Finerenone okay given the data already out. Plus it will likely get a HF indication by as well. For Atacicept even with the positive slope data one trial in 200 patients won’t cut it I suspect in Australia.

010

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 06/11/2025

While I agree, here in Australia the drugs will not get funded by the govt without the harder endpoints unless of course the price is okay which of course is not going to happen. It’s exciting to see all these new therapeutics but unless the cost comes down I doubt we will see them in Australia soon

102

Reposted by Kevan Polkinghorne 🇳🇿

Duke Kidney @dukekidney.bsky.social · 04/11/2025

Dr Edmonston on NEJMgroup covering ASN Kidney Week #KidneyWk cdn.jwplayer.com/pla...

031

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 27/10/2025

Agree. I gave talk to my ID colleagues who still use CG for dosing at their request. They also mentioned another big problem in ID is Augmented renal clearance of antibiotics in patients with burns etc. Being a nephrologist hadn’t really concerned myself with kidney function that’s too good 😂

020

Reposted by Kevan Polkinghorne 🇳🇿

ANZVASC @anzvasc.bsky.social · 17/10/2025

We’re thrilled to welcome Professor Stephen McDonald to the International Vasculitis Workshop 2026! A globally respected expert in vasculitis and nephrology, Prof McDonald brings invaluable insight and experience to the program. Register today at vasculitis-melbourne2026.com

032

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 17/10/2025

Yep. No way will be available in Australia. Is it available for C3GN there?

000

Reposted by Kevan Polkinghorne 🇳🇿

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 08/10/2025

happening tomorrow! @dialysisbloke.bsky.social will be musing on vascular access for #NephGR at @uottawa.ca and @ottawahospital.on.ca

052

Reposted by Kevan Polkinghorne 🇳🇿

Shellie Fravel, PharmD @shelliefravel.bsky.social · 17/09/2025

Should we be considering the variability of a person's BP? Growing evidence that more variability is linked to poor outcomes. Maybe something for the 2033 BP guidelines... Long‐Term Blood Pressure Variability and Physical Performance in Older Adults - onlinelibrary.wiley.com/doi/10.1111/...

onlinelibrary.wiley.com

132

Reposted by Kevan Polkinghorne 🇳🇿

KitchingLab @kitchinglab.bsky.social · 18/09/2025

Last chance everyone! Submit your abstract and join the over 55 invited international speakers at the Workshop #vasculitismelbourne2026 Case reports and series welcome And remember the new Young Invstigator Award Session. See you in 2026.

011

Reposted by Kevan Polkinghorne 🇳🇿

Michael Walsh @lastwalsh.bsky.social · 03/09/2025

Amazing #ANZSN meeting in Perth. First class science (🤯 young investigators), ideas for future meetings, and caught up with friends and colleagues. Melbourne for the vasculitis-melbourne2026.com next!

vasculitis-melbourne2026.com

IVW 2026 | 22nd International Vasculitis Workshop

Join the 22nd International Vasculitis Workshop, a leading event dedicated to advancing research, treatment, and understanding of vasculitis. Connect with global experts, researchers, and practitioner...

051

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 03/09/2025

Yes. Will no doubt be further work to assess this in more detail in time

010

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 03/09/2025

Not sure. Mike didn’t have time to go over in detail.

010

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 03/09/2025

@nephjc.bsky.social @lastwalsh.bsky.social just presented ACHIEVE results at #ANZSN. Here’s a some details of country differences not in the main paper

1125

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 01/09/2025

@kitchinglab.bsky.social Huan presenting his ANCA vasculitis data in the YI session #ANZSN 2025.

040

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 01/09/2025

Prof Liz Lightstone giving us a fantastic update on Lupus Nephritis at #ASNZSN 2025 @kidneydoc101.bsky.social

072

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 01/09/2025

It’s very interesting that this is being done. Shellie and I plus a few others are looking at this more closely Hopefully will have some nice data to get out there.

010

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 01/09/2025

Is this happening in Canadian EMR’s as well?

100

Kevan Polkinghorne 🇳🇿 @dialysisbloke.bsky.social · 01/09/2025

Adeera Levin giving the opening Plenry 60th #ANZSN congress - the past present and future.

020

Reposted by Kevan Polkinghorne 🇳🇿

Australia and New Zealand Dialysis and Transplant Registry @anzdataregistry.bsky.social · 28/08/2025

Dialysis capacity is under pressure in 🇦🇺 & 🇳🇿. ANZDATA + ANZSN are working to understand the impacts. Hear more at #ANZSN Congress (31 Aug-3 Sept): anzsnevents.com Full Report: lnkd.in/eM2Kjdw3 (thanks to @thelimbic @mardichapman for coverage!)

anzsnevents.com

60th ANZSN Congress

033